<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-049661</identifier>
<setSpec>1699-8855</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effects of IFN&amp;#945; and Lymphomyosot on «vitro» and «in vivo» B16F10 melanoma growth. Treatment with IFN&amp;#945; and Lymphomyosot</dc:title>
<dc:description xml:lang="en">Introduction: Several cytokines are being tested in thetreatment of melanoma. Among them IFN&amp;#945; should be highlighted,whilst no other experimental studies using homeopathicproducts are underway. Material &amp; Methods: «Invitro»: the cell line B16F10 was treated at 24, 48 and 72hours with IFN&amp;#945;/10 at 1,000,000 IU/ml and withLymphomyosot 1/1 and 1/3 (v/v). Cell viability was quantifiedusing MTT test. «In vivo»: two experiments werecarried out on 80 male mice which were injected with 1x105B16F10 cells and treated with: I (PBS), II (IFN&amp;#945;), III(Lymphomyosot) and IV (IFN&amp;#945; plus Lymphomyosot). Amorphological study was also performed. Results: «Invitro»: at high concentrations of IFN&amp;#945;, cell growth wasinhibited and Lymphomyosot showed no cytotoxic effects.«In vivo»: IFN&amp;#945; reduced the cell-proliferation rate as wellas the extent of spread of inflammatory infiltrates, whilstLymphomyosot caused a significant tumor weight drop andnecrosis. Conclusion: IFN&amp;#945; displayed cytotoxicity in bothmodels whilst Lymphomyosot had an absence of toxicityand an indirect anti-tumor effect, probably due to an increasein the host's response</dc:description>
<dc:creator>Garc&amp;#237;a Reverte, Juana</dc:creator>
<dc:creator>Pascual Carpe, Fernando</dc:creator>
<dc:creator>Vicente Ortega, Vicente</dc:creator>
<dc:creator>Y&amp;#225;&amp;#241;ez Gasc&amp;#243;n, M. Josefa</dc:creator>
<dc:creator>Campos Aranda, Matilde</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducci&amp;#243;n: En el tratamiento del melanoma se est&amp;#225;nensayando distintas citoquinas, entre las que destaca elIFN&amp;#945;, no existiendo estudios experimentales con productoshomeop&amp;#225;ticos. Material y m&amp;#233;todos: «In vitro» la l&amp;#237;neaB16F10 fue tratada durante 24, 48 y 72 horas con IFN&amp;#945;/10a 1.000.000 UI/ml y con Lymphomyosot 1/1 y 1/3 (v/v),cuantificando la viabilidad celular con el test del MTT. «Invivo» realizamos dos experimentos con 80 ratones machosa los que inyectamos 1X105 c&amp;#233;lulas B16F10 y tratamos con:I (PBS), II (IFN&amp;#945;), III (Lymphomyosot) y IV (IFN&amp;#945; m&amp;#225;sLymphomyosot), realizando el estudio morfol&amp;#243;gico. Resultados:«In vitro» el IFN&amp;#945; a altas concentraciones inhibi&amp;#243; elcrecimiento celular y el Lymphomyosot no mostr&amp;#243; efectoscitot&amp;#243;xicos. «In vivo» el IFN&amp;#945; redujo el &amp;#237;ndice de proliferaci&amp;#243;ncelular y la extensi&amp;#243;n de los infiltrados inflamatorios,mientras que el Lymphomyosot origin&amp;#243; disminuci&amp;#243;n significativade los pesos y necrosis tumorales. Conclusi&amp;#243;n: ElIFN&amp;#945; ha mostrado citotoxicidad en ambos modelos y elLymphomyosot ausencia de toxicidad y efecto antitumoralindirecto probablemente al aumentar la respuesta del hu&amp;#233;sped</dc:description>
<dc:source>Rev. esp. patol;39(1): 27-34, abr. 2006. ilus, tab, graf</dc:source>
<dc:identifier>ibc-049661</dc:identifier>
<dc:title xml:lang="es">Efectos del IFN&amp;#945; y del Lymphomyosot sobre el crecimiento del melanoma B16F10 «in vitro» e «in vivo». Tratamiento con IFN&amp;#945; y Lymphomyosot</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d^s22057</dc:subject>
<dc:subject>^d22921</dc:subject>
<dc:subject>^d30033^s22079</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d19247^s22053</dc:subject>
<dc:subject>^dCITOTOXICIDAD INMUNOL&amp;#243</dc:subject>
<dc:subject>^dNEOPLASIAS CUT&amp;#225</dc:subject>
<dc:type>article</dc:type>
<dc:date>200604</dc:date>
</metadata>
</record>
</ibecs-document>
